Alain Sanchez, MD (@lain_sanchez) header
Alain Sanchez, MD (@lain_sanchez) profile picture

Rheumatologist and Internist @ABCcentromedico | Professor @TECccm Former Research Fellow, Division of rheumatology @MayoClinic, Rochester, MN

Rochester, MN
Joined September 2013
Photo by Alain Sanchez, MD (@lain_sanchez)Photo by Alain Sanchez, MD (@lain_sanchez)Photo by Alain Sanchez, MD (@lain_sanchez)Photo by Alain Sanchez, MD (@lain_sanchez)Photo by Alain Sanchez, MD (@lain_sanchez)Photo by Alain Sanchez, MD (@lain_sanchez)Photo by Alain Sanchez, MD (@lain_sanchez)Photo by Alain Sanchez, MD (@lain_sanchez)Photo by Alain Sanchez, MD (@lain_sanchez)Photo by Alain Sanchez, MD (@lain_sanchez)
The most dangerous phrase in our language is “we have always done it this way” – at Minnesota, USA
2
10
Alain Sanchez, MD retweeted
Not all bone marrow oedema is spondyloarthritis! Osteitis condensans ilii can mimic sacroiliitis on MRI. Recognising its characteristic imaging features is essential to avoid misdiagnosis. #SpA #Spondyloarthritis #OsteitisCondensansIlii
1
25
1
58
2,074
Alain Sanchez, MD retweeted
In lupus nephritis (LN), “activity” gets the spotlight—but chronic scarring often decides the long game. So: which chronicity score best predicts outcomes—NIH Chronicity Index (NIH-CI) or the Mayo Clinic Chronicity Score (MCCS)? buff.ly/tvebmPZ
1
29
56
2,944
Alain Sanchez, MD retweeted
🫁 ERS/EULAR 2026 CTD-ILD Guidelines — Key Takeaways 🔹 Covers SSc, RA, IIM, Sjögren, SLE & MCTD–ILD 🔹 Built on 25 PICO + 28 narrative questions using GRADE methodology 📌 Screening 👉 HRCT = gold standard 🚫 Do NOT replace HRCT with PFTs or lung ultrasound (high miss rates) ✅ Screen ALL SSc & MCTD ✅ Screen RA / SjD / IIM if risk factors present 📌 Baseline risk assessment Assess globally using: • HRCT extent/pattern • FVC + DLCO • Autoantibodies • CRP/ESR • Clinical severity 📌 Monitoring 🔁 PFTs every 3–6 months initially, then 6–12 monthly 🔁 HRCT: • SSc/RA: every 1–2 yrs • IIM (high-risk): as early as 3–6 months 📌 Treatment recommendations 🟢 SSc-ILD • Tocilizumab (strong) • MMF / Rituximab / Cyclophosphamide (conditional) • Nintedanib for progressive fibrosis • MMF + Nintedanib combination allowed 🟢 IIM-ILD • Immunosuppression strongly recommended 🟢 RA / SjD / SLE / MCTD-ILD • Immunosuppressants suggested • RA-ILD (UIP): Pirfenidone may help 🟢 Progressive fibrosing CTD-ILD • Add Nintedanib 🚫 Lung biopsy NOT routine ✅ BAL only if infection / alternate dx suspected ✅ PROMs + 6MWT for severity/prognosis ⸻ 🔥 TAKE-HOME MESSAGE Early HRCT screening + structured monitoring + timely immunosuppression/antifibrotics = cornerstone of CTD-ILD care. Missing ILD = missed survival opportunity. ⸻ 📄 Eur Respir J 2026 DOI: 10.1183/13993003.02533-2024 #CTDILD #InterstitialLungDisease #Rheumatology #Pulmonology #SystemicSclerosis #RA #Myositis #Sjogrens #SLE #ERS #EULAR #ILD #MedTwitter #RheumTwitter #PulmTwitter
4
83
1
227
11,086
Alain Sanchez, MD retweeted
Volver a México y compartir con colegas siempre es una alegría: colegas increíbles, preguntas buenísimas y mucha conversación. Gracias al Colegio Mexicano de Reumatología por la invitación. 🇲🇽
3
13
732
Alain Sanchez, MD retweeted
Call for new applicants for Rheum With a (re)View—a mentoring program focused on cultivating manuscript reviewers for the ACR’s 3 scientific journals. ACR/ARP members with research experience are encouraged to apply by March 31 ▶️ Details → rheumatology.org/acr-journal…
1
5
640
🆕 2025 ACR Guideline for Treatment of Systemic #Lupus Erythematosus 🦋 Just Released: Nov 3 #ACR25 🔥 🔸Review organ-specific treatment recommendations 🔸Steroid & HCQ Use Guidance ➠ Read the Full Guideline: acr.tw/47mkegj #RheumX #RheumTwitter #Rheum @RheumNow
2
117
3
317
33,093
Alain Sanchez, MD retweeted
Now published: The 2025 ACR Guideline for the Treatment of Systemic Lupus Erythematosus 📄 Read the paper: acr.tw/47mkegj ℹ️ See additional content and resources on this guideline at acr.tw/4mbHK4W
1
128
329
21,612
Over 20 years have passed since the ACR last issued a broad treatment guideline for #SLE. In our NEWEST episode, Lisa R. Sammaritano, MD, summarizes the major updates in the soon-to-be-released 2025 guideline.🎙️LISTEN → acr.tw/4mTmpNi
8
1
14
869
#ESOC2025 🏃🏻‍♀️ESCAPE MEVO sub analysis 👉🏻 prognosis by image 🧠 👉🏻EVT <12 hs not > good functional outcome 👉🏻 Good collateral status > benefit 👉🏻 ⏱️<180 min > benefit
1
28
2
71
6,070
Alain Sanchez, MD retweeted
1/ 🧵The 2024 ACR Guidelines for Lupus Nephritis (LN) are here! Big shifts in screening, combo therapy, and steroid minimization. Let's break it down. Full text: acrjournals.onlinelibrary.wi…
1
53
4
123
12,474
Alain Sanchez, MD retweeted
Now published simultaneously in AC&R + A&R, the 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis See ACR guideline page for resources - rheumatology.org/lupus-guide… DOI link - doi.org/10.1002/acr.25528 Download the article - acr.tw/44sRwJM
1
70
8
175
53,519
Alain Sanchez, MD retweeted
Welcome Jaime! 🤩⭐️🤩⭐️
Grateful and ready for the new adventure!
2
2
38
7,311
Alain Sanchez, MD retweeted
Rheumatologist when someone automatically calls an ANA (+) “undifferentiated connective tissue disease”
2
7
1
28
4,846
NEW! Curious about how genetics influence autoimmune disease risk? Tune in & hear from @HocaogluMd, who dives into the study of antinuclear antibody production using data from the All of Us Research Program → acr.tw/42d7QN2 @ACR_Journals
6
8
1,084
Alain Sanchez, MD retweeted
🔟 Final Takeaways ✅ Obi improved renal outcomes in active LN ✅ Steroid-sparing effect (more Obi pts tapered to ≤7.5 mg/day) ✅ Proteinuria reduction = better long-term kidney survival ✅ Infections (esp. COVID-19) are a key safety concern
2
5
19
1,088
Alain Sanchez, MD retweeted
🚨 Breaking down the REGENCY trial 🚨 A Phase 3 RCT evaluating obinutuzumab (Obi) in lupus nephritis (LN). Let's dive into the study design, key findings, and the dosing regimens! 🧵⬇️
3
36
1
111
13,690
Alain Sanchez, MD retweeted
🚨 New Review Alert! 🚨 Dive into the evolving landscape of glucocorticoid therapy for lupus nephritis: 🔍 Historical shifts from high-dose to safer, low-dose strategies 🧬 Mechanisms, efficacy, & risks explored ⚖️ Balancing treatment efficacy with long-term safety
Now online in @NDTsocial Optimal Glucocorticoid Therapy in Lupus Nephritis 🧐The review examines different dosing strategies, including IV pulse and oral regimens, and presents evidence of their efficacy and safety. ▶️academic.oup.com/ndt/article…
1
13
1
44
4,450